Is Shree Ganesh Rem overvalued or undervalued?

As of 10 October 2025, the valuation grade for Shree Ganesh Rem has moved from expensive to fair. The company is currently fairly valued, with a PE ratio of 29.32, an EV to EBIT of 22.96, and a ROCE of 19.10%. In comparison to peers, Sun Pharma has a higher PE ratio of 34.96 and an EV to EBITDA of 23.7, while Cipla is more attractively valued with a PE of 23.39 and an EV to EBITDA of 16.48.
Despite the recent stock performance showing a decline of 21.58% year-to-date compared to a 5.58% gain in the Sensex, Shree Ganesh Rem's valuation appears reasonable given its current ratios and peer comparisons. The PEG ratio of 0.00 suggests that the company may have growth potential not reflected in its current price, reinforcing the fair valuation assessment.